What’s Propelling Biospecifics Tech Corporation (NASDAQ:BSTC) After Higher Shorts Reported?

September 17, 2017 - By Marguerite Chambers

 What’s Propelling Biospecifics Tech Corporation (NASDAQ:BSTC) After Higher Shorts Reported?

Investors sentiment decreased to 1.26 in Q4 2016. Its down 0.16, from 1.42 in 2016Q3. It fall, as 8 investors sold BioSpecifics Technologies Corp. shares while 31 reduced holdings. 16 funds opened positions while 33 raised stakes. 3.87 million shares or 3.17% more from 3.75 million shares in 2016Q3 were reported.
Moreover, Strs Ohio has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 4,700 shares. Rice Hall James Lc holds 0.37% or 132,015 shares. First Quadrant Ltd Partnership Ca has invested 0.04% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Renaissance Technologies Ltd Co holds 0.03% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 332,746 shares. State Bank Of New York Mellon Corp, New York-based fund reported 67,418 shares. Clarivest Asset Mngmt Ltd Limited Liability Company reported 0.02% stake. Cadence Limited Liability Corporation stated it has 0.08% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Rhumbline Advisers has invested 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Blackrock Grp reported 4,250 shares stake. Acadian Asset Mngmt Llc holds 0.05% or 191,127 shares in its portfolio. Gsa Capital Prns Limited Liability Partnership has 0.14% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Prudential has invested 0.01% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Blackrock Incorporated has invested 0% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). National Bank & Trust Of America De accumulated 1,118 shares. Elk Creek Ltd Limited Liability Company reported 0.55% in BioSpecifics Technologies Corp. (NASDAQ:BSTC).

The stock of Biospecifics Tech Corporation (NASDAQ:BSTC) registered an increase of 6.56% in short interest. BSTC’s total short interest was 139,700 shares in September as published by FINRA. Its up 6.56% from 131,100 shares, reported previously. With 21,600 shares average volume, it will take short sellers 7 days to cover their BSTC’s short positions. The short interest to Biospecifics Tech Corporation’s float is 3.27%.

The stock decreased 1.90% or $0.91 on September 15, reaching $47.1. About 70,484 shares traded or 176.79% up from the average. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has risen 49.91% since September 17, 2016 and is uptrending. It has outperformed by 33.21% the S&P500.

BioSpecifics Technologies Corp. is a biopharmaceutical firm involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The company has market cap of $337.44 million. The Firm has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability firm , an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. It has a 28.77 P/E ratio. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe).

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Ratings Coverage

Among 2 analysts covering BioSpecifics Technologies Corp (NASDAQ:BSTC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioSpecifics Technologies Corp had 2 analyst reports since March 8, 2016 according to SRatingsIntel. The stock of BioSpecifics Technologies Corp. (NASDAQ:BSTC) has “Buy” rating given on Thursday, August 10 by H.C. Wainwright. The stock of BioSpecifics Technologies Corp. (NASDAQ:BSTC) earned “Buy” rating by Rodman & Renshaw on Tuesday, March 8.

More notable recent BioSpecifics Technologies Corp. (NASDAQ:BSTC) news were published by: Prnewswire.com which released: “BioSpecifics Technologies Corp. Reports First Quarter 2017 Financial Results” on May 10, 2017, also Prnewswire.com with their article: “BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2014 …” published on March 13, 2015, Seekingalpha.com published: “Biospecifics Technology Corp.: Underfollowed And Undervalued” on April 21, 2016. More interesting news about BioSpecifics Technologies Corp. (NASDAQ:BSTC) were released by: Marketwatch.com and their article: “47.10” published on January 31, 2011 as well as Prnewswire.com‘s news article titled: “BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of …” with publication date: November 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.